Denali Therapeutics

Quarterly Financials

Values in thousands 2024-06-30 2024-03-31 2023-12-31
Revenue
$0
$0
$-305,043
Gross Profit
-1,942
-2,162
-307,220
EBITDA
-114,651
-130,090
-130,365
EBIT
-116,593
-132,252
-132,542
Net Income
-99,026
-101,802
-119,473
Net Change In Cash
0
0
-305,043
Free Cash Flow
-96,006
-115,770
-100,892
Cash
74,679
60,574
127,106
Basic Shares
168,831
149,404
138,245

Annual Financials

Values in thousands 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Revenue
$330,531
$108,463
$48,661
$335,659
Gross Profit
-93,345
101,431
48,661
335,659
EBITDA
-179,973
-330,361
-287,158
71,249
EBIT
-196,699
-337,393
-295,751
62,718
Net Income
-145,224
-325,991
-290,581
71,136
Net Change In Cash
330,531
108,463
48,661
335,659
Cost of Revenue
-213,667
427,695
Free Cash Flow
-370,930
-262,549
-219,889
413,057
Cash
127,106
218,044
293,477
507,144
Basic Shares
137,370
125,530
121,524
112,703

Earnings Calls

Quarter EPS
2024-09-30
-$0.63
2024-06-30
-$0.59
2024-03-31
-$0.78
2023-12-31
-$0.86